|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Pittsburgh |
|---|---|
| Information provided by: | University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00462579 |
Purpose
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.
| Condition |
|---|
|
Acinetobacter Infections |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Risk Factors for Carbapenem-resistant Acinetobacter Baumannii |
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | December 2013 |
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.he following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
carbapenem-resistant acinetobacter baumannii positive cultures
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: David L Paterson, MD | 412-648-6401 | patersond@dom.pitt.edu |
| Contact: Diana Lynn Pakstis, RN, BSN | 412-648-6553 | pakstisdl@dom.pitt.edu |
| United States, Pennsylvania | |
| UPMC | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: David L Paterson, MD 412-648-6401 patersond@dom.pitt.edu | |
| Contact: Diana Lynn Pakstis, RN, BSN 412-648-6553 pakstisdl@dom.pitt.edu | |
| Principal Investigator: | David L Paterson, MD | University of Pittsburgh |
More Information
| Responsible Party: | David Paterson, MD, UPMC |
| ClinicalTrials.gov Identifier: | NCT00462579 History of Changes |
| Other Study ID Numbers: | PRO07040057 |
| Study First Received: | April 17, 2007 |
| Last Updated: | February 17, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
carbapenem-resistant acinetobacter baumannii positive culture positive culture for carbapenem-resistant acinetobacter |
|
Acinetobacter Infections Moraxellaceae Infections Gram-Negative Bacterial Infections Bacterial Infections |